Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

The understanding of second‐line use of glucose‐lowering drugs (GLDs) in the general population with type 2 diabetes (T2D) treatment is important as recent results have shown cardiovascular benefits with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA). Our aim was to describe second‐line GLD treatment patterns in four Nordic countries.

[1]  B. Shields,et al.  Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017 , 2018, Diabetes, obesity & metabolism.

[2]  S. Schneeweiss,et al.  Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study , 2018, British Medical Journal.

[3]  K. Khunti,et al.  Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany , 2017, Diabetes, obesity & metabolism.

[4]  Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 , 2017, PharmacoEconomics - Open.

[5]  B. Carstensen,et al.  Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. , 2017, The Lancet Diabetes and Endocrinology.

[6]  B. Carstensen,et al.  Dapagliflozin Compared to DPP-4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic): a multinational observational study. , 2017 .

[7]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[8]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .

[9]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[10]  J. Eriksson,et al.  Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[11]  K. Khunti,et al.  Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. , 2017, Primary care diabetes.

[12]  J. Eriksson,et al.  Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. , 2017, Diabetes research and clinical practice.

[13]  H. Bøtker,et al.  Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study , 2016, BMJ Open.

[14]  S. Gudbjörnsdottir,et al.  Cardiovascular safety of glucose‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register , 2016, Diabetes, obesity & metabolism.

[15]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[16]  O. Pedersen,et al.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.

[17]  J. Eriksson,et al.  Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. , 2016, Diabetes research and clinical practice.

[18]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[19]  J. Eriksson,et al.  Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013 , 2016, Diabetologia.

[20]  J. Eriksson,et al.  Comparison of use of diabetic medication and clinical guidelines in four Nordic countries , 2016, Annals of medicine.

[21]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[22]  D. Tarng,et al.  Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. , 2015, Annals of internal medicine.

[23]  J. Bodegård,et al.  Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  S. Nygård,et al.  [Diagnostic accuracy for heart failure – data from the Akershus Cardiac Examination 2 Study]. , 2015, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[25]  Ju-Young Kim,et al.  Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study , 2015, PloS one.

[26]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[27]  A. Vaag,et al.  Cardiovascular safety of combination therapies with incretin‐based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study , 2014, Diabetes, obesity & metabolism.

[28]  C. Currie,et al.  Combination therapy with metformin plus sulphonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality , 2014, Diabetes, obesity & metabolism.

[29]  A. Hung,et al.  Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. , 2014, JAMA.

[30]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[31]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[32]  L. Køber,et al.  Accuracy of a heart failure diagnosis in administrative registers , 2008, European journal of heart failure.

[33]  E. Ingelsson,et al.  The validity of a diagnosis of heart failure in a hospital discharge register , 2005, European journal of heart failure.